The Department of General Surgery, The Ganzhou People's Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Ganzhou, PR China.
Medicine (Baltimore). 2021 Apr 30;100(17):e25658. doi: 10.1097/MD.0000000000025658.
The aim of this study was to investigate the expression of phosphatase of regenerating live-3 (PRL-3) in human stage III colorectal cancer (CRC) and to evaluate its correlation with metachronous liver metastasis (MLM) and prognosis.The retrospective cohort study included 116 stage III CRC primary tumors and 60 normal colorectal tissues. PRL-3 expression was measured by immunohistochemistry. We investigated the correlation of PRL-3 with clinicopathologic features by the chi-square test. The association of PRL-3 expression with MLM was assessed by binary logistic regression. Overall survival (OS) and disease-free survival (DFS) between patients with positive PRL-3 expression and those with negative PRL-3 expression were compared by the Kaplan-Meier method and Cox proportional hazards regression model.We found that 32.8% of stage III CRC primary tumors were PRL-3 positive, and 15.0% of normal colorectal epithelia showed high PRL-3 expression (P = .012). Seventeen tumors (47.2%) among 36 cases that developed MLM were PRL-3 positive, and only 21 tumors (26.3%) in the 80 cases that did not develop MLM had positive PRL-3 expression (P = .026). PRL-3 expression was associated with MLM (P = .028). Patients with positive expression of PRL-3 showed a significantly shorter OS (40.32 ± 3.97 vs 53.96 ± 2.77 months, P = .009) and DFS (34.97 ± 4.30 vs 44.48 ± 2.89 months, P = .036). A multivariate analysis indicated that PRL-3 expression was an independent unfavorable prognostic factor for OS (P = .007).Our study suggested that high PRL-3 expression is an independent risk factor for MLM and poor prognosis. PRL-3 is expected to be a promising biomarker for predicting the incidence of MLM and prognosis in patients with stage III CRC.
本研究旨在探讨磷酸酶再生肝脏 3（PRL-3）在人结直肠癌（CRC）III 期的表达，并评估其与异时性肝转移（MLM）和预后的相关性。本回顾性队列研究纳入了 116 例 III 期 CRC 原发肿瘤和 60 例正常结直肠组织。采用免疫组织化学法检测 PRL-3 表达。我们通过卡方检验研究了 PRL-3 与临床病理特征的相关性。采用二项逻辑回归评估 PRL-3 表达与 MLM 的相关性。通过 Kaplan-Meier 方法和 Cox 比例风险回归模型比较 PRL-3 阳性表达患者与阴性表达患者的总生存期（OS）和无病生存期（DFS）。我们发现，32.8%的 III 期 CRC 原发肿瘤为 PRL-3 阳性，15.0%的正常结直肠上皮高表达 PRL-3（P=0.012）。36 例发生 MLM 的病例中有 17 例（47.2%）肿瘤为 PRL-3 阳性，80 例未发生 MLM 的病例中有 21 例（26.3%）肿瘤 PRL-3 阳性（P=0.026）。PRL-3 表达与 MLM 相关（P=0.028）。PRL-3 阳性表达患者的 OS（40.32±3.97 比 53.96±2.77 个月，P=0.009）和 DFS（34.97±4.30 比 44.48±2.89 个月，P=0.036）明显缩短。多因素分析表明，PRL-3 表达是 OS 的独立不良预后因素（P=0.007）。本研究表明，高 PRL-3 表达是 MLM 和不良预后的独立危险因素。PRL-3 有望成为预测 III 期 CRC 患者 MLM 发生率和预后的有前途的生物标志物。
